Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD40/TNFRSF5 Antibody (SAA1387)

Catalog #:   FHD68930 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1, kappa
Applications: FCM
Accession: P25942
Overview

Catalog No.

FHD68930

Species reactivity

Human

Host species

Mouse

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P25942

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.09% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1387

Data Image
  • Bioactivity
    Detects CD40/TNFRSF5 in indirect ELISAs.
  • Flow-cytometry
    Flow-cytometry using anti-human CD40 antibody.Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD40 antibody monoclonal antibody (Catalog # FHD68930 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-mouse antibody (Catalog # PMB96441) and cells analysed on a NovoCyte Flow Cytometer.
References

Mechanistic investigation of calcium phosphate mineralization potentiating the cellular immune response of foot-and-mouth disease virus-like particle vaccines., PMID:40512119

Synergy and antagonism in the integration of BCR and CD40 signals that control B-cell population expansion., PMID:40473841

A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity., PMID:40441493

Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform., PMID:40417977

Adoptively transferred macrophages for cancer immunotherapy., PMID:40413021

Advances in Subclinical and Clinical Trials and Immunosuppressive Therapies in Xenotransplantation., PMID:40387233

Single Treatment Boiling Histotripsy Focused Ultrasound Ablation Neither Negates nor Enhances the Activity of α-CD40 in a Pancreatic Cancer Model., PMID:40372859

Mechanisms of tumor-associated macrophages promoting tumor immune escape., PMID:40371816

Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice., PMID:40360777

Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis., PMID:40358149

Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data., PMID:40347227

Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells., PMID:40341026

The role of soluble CD40L in autoimmune diseases., PMID:40329996

Identification of soluble biomarkers that associate with distinct manifestations of long COVID., PMID:40307449

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis., PMID:40300121

Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant., PMID:40285479

Multi-epitope microsphere vaccine modified immunological efficacy against LMBV in largemouth bass (Micropterus salmoides)., PMID:40279807

Aerosol Delivery of Hesperetin-Loaded Nanoparticles and Immunotherapy Increases Survival in a Murine Lung Cancer Model., PMID:40278452

Berberine Suppression of Human IgE but Not IgG Production via Inhibition of STAT6 Binding Activity at IgE Promoter by BCL6., PMID:40277916

A promising endeavor against human cytomegalovirus: Predominant epitopes-based recombinant subunit vaccine RHEcIE1/pp65/pp150., PMID:40277436

CD40 promotes AML survival via non-canonical NF-κB signaling and aberrant lipid metabolism., PMID:40252467

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity., PMID:40246582

OMIP-113: Characterization of Cytokine Producing T Cells in Swine., PMID:40231482

The immune checkpoint regulator CD40 potentiates myocardial inflammation., PMID:40217124

Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling., PMID:40217113

Recognition of different subsets of alloreactive T cells by activation-induced markers., PMID:40204006

CAR Treg synergy with anti-CD154 promotes infectious tolerance and dictates allogeneic heart transplant acceptance., PMID:40197364

Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway., PMID:40170058

Integrative miRNA-mRNA profiling uncovers mechanisms of belimumab action in systemic lupus erythematosus., PMID:40160819

Targeted immunotherapies for Graves' thyroidal & orbital diseases., PMID:40145088

Facts and Hopes of CD40 Agonists in Cancer Immunotherapy., PMID:40117130

Lupenone preserves T cell activity by recovery of CD40L expression and protection from cytotoxicity due to methamphetamine exposure., PMID:40111983

Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity., PMID:40111090

Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: An exploratory, phase II maintenance trial., PMID:40104960

Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement., PMID:40090010

Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors., PMID:40074330

Suppression of NF-κB and downstream XBP1 by DcR3 contributes to a decrease in antibody secretion., PMID:40073262

Comparison of human macrophages derived from peripheral blood and bone marrow., PMID:40073092

Elevated serum CD40 as a potential biomarker for the differential diagnosis of acute thyrotoxic myopathy., PMID:40069315

Influence of environmental exposures on T follicular helper cell function and implications on immunity: a comparison of Bangladeshi and American children., PMID:40062864

IL-1R1 Blockade Boosts CD40 Agonist Immune Responses but Fails to Improve Efficacy or Reduce Hepatotoxicity in Pancreatic Cancer., PMID:40060615

Humanized FcεRI Expressed on Mouse Eosinophils Mediates IgE-Facilitated Eosinophil Antigen Presentation., PMID:39996772

Modified CD40L-Activated B-Cell Proliferation Model for Validating the Suppressive Activity of CD40-CD154 Pathway Inhibitors., PMID:39994946

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer., PMID:39972124

Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer., PMID:39969975

CD40 induces PIR-A+ macrophages to promote chronic allograft rejection., PMID:39954660

Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy., PMID:39941108

Discrimination of Anti-Donor Response in Allogeneic Transplantation Using an Alloreactive T-Cell Detection Assay., PMID:39936124

Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury., PMID:39935575

Deficiency of adenosine deaminase 2 skews adaptive immune repertoires toward specific sets of T- and B-cell receptors., PMID:39924119

Datasheet
$ 225
Product specifications
50 μg 225 100 μg 372

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD40/TNFRSF5 Antibody (SAA1387) [FHD68930]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only